2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Relapsed Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Relapsed Diffuse Large B-Cell Lymphoma trials Research Report on Relapsed Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
| Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy Atezolizumab, Rituximab, Gemcitabine 1000 mg - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University Hospital Southampton NHS Foundation Trust | 53 | 2018-05-09 | 2022-08-22 |
Lymphoma, Large B-Cell, Diffuse (2) · Recurrence (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Gemcitabine (2) · Oxaliplatin (2) · Rituximab (1) · atezolizumab (1)
Molecular Templates, Inc. (1) · University Hospital Southampton NHS Foundation Trust (1)
United Kingdom (1) · United States (1)
Andy Davies (1)
2016 (1)